Brain Advance Access published online on October 3, 2006
Brain, doi:10.1093/brain/awl274
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA; Laboratory of Neuro Imaging, David Geffen School of Medicine, UCLA, CA, USA
* To whom correspondence should be addressed. Alzheimer's disease is the most common neurodegenerative disorder in the elderly. Amnestic mild cognitive impairment (MCI) is a relatively newly defined clinical entity that requires memory decline while activities of daily living remain intact. Most amnestic MCI patients develop Alzheimer's disease. Using an innovative surface-based hippocampal analytic technique we analysed the structural magnetic resonance hippocampal data of 31 amnestic MCI and 34 Alzheimer's disease subjects. We tested the hypothesis that Alzheimer's disease subjects have greater atrophy of the CA1, CA2 and CA3 hippocampal subfields relative to amnestic MCI subjects. 3D hippocampal maps localized the main group differences to the CA1 region bilaterally and the CA2 and CA3 region on the right (left P = 0.0024, right P = 0.0002, both corrected for multiple comparisons). Age, race, gender, education and Mini-Mental State Examination were significant predictors of hippocampal volume. Hippocampal volume was a significant predictor of clinical diagnosis. Our study suggests that as Alzheimer's disease progresses, subregional hippocampal atrophy spreads in a pattern that follows the known trajectory of neurofibrillary tangle dissemination. Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool.
Received June 7, 2006
Revised August 31, 2006
Accepted August 31, 2006
Article
3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
Liana G. Apostolova 1 *, Ivo D. Dinov 2, Rebecca A. Dutton 3, Kiralee M. Hayashi 3, Arthur W. Toga 1, Jeffrey L. Cummings 4, and Paul M. Thompson 1
2 Laboratory of Neuro Imaging, David Geffen School of Medicine, UCLA, CA, USA; Department of Statistics, David Geffen School of Medicine, UCLA, CA, USA
3 Laboratory of Neuro Imaging, David Geffen School of Medicine, UCLA, CA, USA
4 Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, CA, USA
Liana G. Apostolova, E-mail: lapostolova{at}mednet.ucla.edu
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. D. Louis, A. M. Brickman, C. DeCarli, S. A. Small, K. Marder, N. Schupf, and T. R. Brown Quantitative Brain Measurements in Community-Dwelling Elderly Persons With Mild Parkinsonian Signs Arch Neurol, December 1, 2008; 65(12): 1649 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Fleisher, S. Sun, C. Taylor, C. P. Ward, A. C. Gamst, R. C. Petersen, C. R. Jack Jr, P. S. Aisen, L. J. Thal, and For the Alzheimer's Disease Cooperative Study Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment Neurology, January 15, 2008; 70(3): 191 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Apostolova, C. A. Steiner, G. G. Akopyan, R. A. Dutton, K. M. Hayashi, A. W. Toga, J. L. Cummings, and P. M. Thompson Three-Dimensional Gray Matter Atrophy Mapping in Mild Cognitive Impairment and Mild Alzheimer Disease Arch Neurol, October 1, 2007; 64(10): 1489 - 1495. [Abstract] [Full Text] [PDF] |
||||

